🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Cancer Discovery(2020)10.1158/2159-8290.cd-19-0116Source: DataRank Database

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma is a research paper published in Cancer Discovery (2020). On theSindex it has a DataRank of 0. It has been cited 159 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access159 citations

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 7.98)OA: bronzeTopics (84)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (29)

Saber Tadros ORCID,Matt Teater ORCID,Lorena Fontán ORCID,Aaron Y. Chang ORCID,Neeraj Jain ORCID

Live enrichment

PubMed:31915197 PMC:PMC7275250 OpenAlex:https://openalex.org/W3000215297

HHS | NIH | National Cancer Institute

Grant: CA201380

HHS | NIH | National Cancer Institute

Grant: CA055349

HHS | NIH | National Cancer Institute

Grant: CA192937

HHS | NIH | National Cancer Institute

Grant: CA016672

HHS | NIH | National Cancer Institute

Grant: CA008748

HHS | NIH | National Cancer Institute

Grant: CA178765

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R01 CA178765

NIH HHS

Grant: U54 OD020355

NCI NIH HHS

Grant: R35 CA241894

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: R01 CA055349

NCI NIH HHS

Grant: P01 CA229100

NCI NIH HHS

Grant: R01 CA201380

NCI NIH HHS

Grant: P50 CA192937

National Institutes of Health

Grant: 5P50CA192937-02

MSK SPORE in Lymphoma

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 2R01CA055349-16A2

Biology of Alpha Particle Immunotherapy

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5R01CA201380-04

Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation

National Institutes of Health

Grant: 5U54OD020355-04

MSKCC Pilot Center for Precision Disease Modeling

National Institutes of Health

Grant: 4R01CA178765-04

Transcriptional regulatory mechanisms in B cell development and leukemogenesis

FWCI

7.98

Citation Percentile

1.0%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

bronze

journalhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/3/440.full.pdf

publisherhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/3/440.full.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/10/3/440/1813368/440.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-19-0116

repositoryhttps://pubmed.ncbi.nlm.nih.gov/31915197

Fields of Study

Histone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsCancer-related gene regulation0301 basic medicine03 medical and health sciencesAnimalsAntigen-Presenting CellsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCREB-Binding ProteinCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21EpigenomeGenes, MHC Class IHistocompatibility Antigens Class IIHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesHumansImmune Checkpoint InhibitorsImmune SystemInterferonsLymphocytes, Tumor-InfiltratingLymphomaMiceMutationProto-Oncogene Proteins c-bcl-6Signal TransductionHistone Deacetylase 3

MeSH Terms

EpigenomeImmune Checkpoint InhibitorsHistone Deacetylase 3AnimalsAntigen-Presenting CellsHistocompatibility Antigens Class IIAntineoplastic Combined Chemotherapy ProtocolsGenes, MHC Class IHistone DeacetylasesHumansImmune SystemInterferonsLymphomaMutationSignal TransductionLymphocytes, Tumor-InfiltratingCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21CREB-Binding ProteinMiceHistone AcetyltransferasesProto-Oncogene Proteins c-bcl-6Histone Deacetylase InhibitorsB7-H1 Antigen

Keywords

Immune surveillanceLymphomaImmune systemHDAC3Computational biologyCancer researchBiologyImmunologyGeneticsGeneCyclin-Dependent Kinase Inhibitor p21Histocompatibility Antigens Class IIAntigen-Presenting CellsGenes, MHC Class ICREB-Binding ProteinB7-H1 AntigenHistone DeacetylasesHistone Deacetylase InhibitorsEpigenomeLymphocytes, Tumor-InfiltratingCell Line, TumorCREBBP, HDAC3, Interferon, MHC class IIAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansInterferonsImmune Checkpoint InhibitorsCell ProliferationHistone Acetyltransferases

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (7)

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Blood Cancer Journal(2020)

co-cited

10.1038/s41408-020-00340-z

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

N/A

3.0DataRank · unranked

Cancer Cell(2020)

co-cited

10.1016/j.ccell.2020.04.004

Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition

N/A

0.675DataRank · unranked

Trends in Immunology(2020)

co-cited

10.1016/j.it.2020.08.010

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes

Blood Advances(2020)

co-cited

10.1182/bloodadvances.2020002580

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

N/A

5.4DataRank · unranked

Cancer Cell(2021)

co-cited

10.1016/j.ccell.2021.10.006

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

N/A

0.631DataRank · unranked

Blood Cancer Journal(2021)

co-cited

10.1038/s41408-021-00521-4

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

N/A

1.4DataRank · unranked

Nature(2000)

co-cited

10.1038/35000501